Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NeuroFront Acquires Non-Opioid Neuropathic Pain Killer for $130 Million

publication date: Jul 21, 2022

Hong Kong’s NeuroFront Therapeutics acquired greater China rights to a novel non-opioid neuropathic pain drug from Switzerland’s Novaremed in a $130 million agreement. NeuroFront, a company focusing on innovative CNS drugs, will initially develop NRD.E1 to treat diabetes-related neuropathic pain. It will pay $130 million in option and milestone payments for commercialization and manufacturing rights, plus royalties on sales. The company must exercise its license option no later than completion of the Phase IIb trial of NRD.E1 in PDPN, which will start patient enrollment in the next few weeks. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital